Abstract
Phosphodiesterases (PDEs) have gained attention as potential pharmacological targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP. It is well-known the relationship between cAMP signaling and inflammation. Since neuroinflammation is considered to play an important role in the pathology of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies. PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia. Enhancing the intracellular concentration of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.
Keywords: cAMP, Cognitive Impairment, Depression, Phosphodiesterase, inhibitors, Schizophrenia.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders
Volume: 16 Issue: 29
Author(s): Ana M. Garcia, Ana Martinez and Carmen Gil
Affiliation:
Keywords: cAMP, Cognitive Impairment, Depression, Phosphodiesterase, inhibitors, Schizophrenia.
Abstract: Phosphodiesterases (PDEs) have gained attention as potential pharmacological targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP. It is well-known the relationship between cAMP signaling and inflammation. Since neuroinflammation is considered to play an important role in the pathology of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies. PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia. Enhancing the intracellular concentration of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.
Export Options
About this article
Cite this article as:
Garcia M. Ana, Martinez Ana and Gil Carmen, Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders, Current Topics in Medicinal Chemistry 2016; 16 (29) . https://dx.doi.org/10.2174/1568026616666160426151306
DOI https://dx.doi.org/10.2174/1568026616666160426151306 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advancements in the Understanding of Paclitaxel Metabolism in Tissue Culture
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Pro-Inflammatory Processes in the Alzheimers Pathology (Guest Editor: A. Claudio Cuello)]
Current Alzheimer Research The Effects of Speech Therapy and Pharmacological Treatments on Voice and Speech in Parkinsons Disease: A Review of the Literature
Current Medicinal Chemistry Dopamine D5 Receptors: A Challenge to Medicinal Chemists
Mini-Reviews in Medicinal Chemistry Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Editorial [ Drug Discovery for Alzheimers Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ]
Current Alzheimer Research Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research Regulatory T-Cells: Immunomodulators in Health and Disease
Current Topics in Medicinal Chemistry Ca<sub>v</sub>1.3 Channels as Key Regulators of Neuron-Like Firings and Catecholamine Release in Chromaffin Cells
Current Molecular Pharmacology Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions
Current Pharmacogenomics Early Pathogenesis of Atherosclerosis: The Childhood Obesity
Current Pharmaceutical Design Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Drug-Related Decrease in Neuropsychological Functions of Abstinent Drug Users
Current Drug Abuse Reviews The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology The Molecular Mechanism of MAPK / ERK Inactivation
Current Genomics Cardioprotective Effects of the I<sub>f</sub> Current Inhibition by Ivabradine During Cardiac Dysfunction
Current Pharmaceutical Biotechnology Role of Transcranial Doppler Ultrasonography in Cerebrovascular Disease
Recent Patents on CNS Drug Discovery (Discontinued) Recent Evidence Regarding a Role for Cdk5 Dysregulation in Alzheimers Disease
Current Alzheimer Research α,β-Acetylenic Amino Thiolester Inhibitors of Aldehyde Dehydrogenases 1&3: Suppressors of Apoptogenic Aldehyde Oxidation and Activators of Apoptosis
Current Medicinal Chemistry Proton Magnetic Resonance Spectroscopy as a Monitoring Tool for Electroconvulsive Therapy Effects on the Brain
Current Psychiatry Reviews